Arromax Pharmatech

Arromax Pharmatech is a high-tech biopharmaceutical and contract research/manufacturing organization (CRO/CDMO) based in Suzhou, China. Founded in 2011, the company specializes in the discovery, process development, and manufacturing of high-quality Active Pharmaceutical Ingredients (APIs), key intermediates, and innovative small molecule drugs. Their internal discovery chemistry research focuses heavily on oncology, cardiovascular diseases, and diabetes, with notable research programs in next-generation kinase inhibitors (targeting EGFR, BTK, ALK, and multikinases) and EP4 antagonists. Arromax provides custom synthesis, process optimization, and drug quality studies to global pharmaceutical partners while advancing its own preclinical discovery programs.